Key Inclusion Criteria:

        Diagnosis of B-cell lymphoma, CLL or B-ALL as described below:

        B-Cell Lymphoma:

          -  Histologically documented lymphomas expected to express CD19

          -  Relapsed/refractory disease following at least 2 prior lines of multi-agent
             immunochemotherapy

        Chronic Lymphocytic Leukemia (CLL):

          -  Diagnosis of CLL per iwCLL guidelines

          -  Relapsed/refractory disease following at least two prior systemic treatment regimens

        Precursor B-cell Acute Lymphocytic Leukemia (B-ALL):

          -  Diagnosis of B-ALL by flow cytometry, bone marrow histology, and/or cytogenetics

          -  Relapsed/refractory disease after at least 2 cycles of standard multiagent induction
             chemotherapy. For subjects with Philadelphia-chromosome positive (Ph+) disease,
             failure or intolerance to a tyrosine kinase inhibitor therapy-containing regimen

        ALL SUBJECTS:

          -  Capable of giving signed informed consent

          -  Age ≥ 18 years old

          -  Stated willingness to comply with study procedures and duration

          -  Contraceptive use for women and men as defined in the protocol

        Key Exclusion Criteria:

        ALL SUBJECTS:

          -  Females who are pregnant or breastfeeding

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status ≥2

          -  Body weight <50 kg

          -  Evidence of insufficient organ function

          -  Receipt of therapy within 2 weeks prior to Day 1 or five half-lives, whichever is
             shorter; or any investigational therapy within 28 days prior to Day 1

          -  Currently receiving or likely to require systemic immunosuppressive therapy

          -  Ongoing requirement for systemic GvHD therapy following prior allogeneic hematopoietic
             stem cell transplant (HSCT) or allogeneic CAR-T

          -  Receipt of an allograft organ transplant

          -  Known active central nervous system (CNS) involvement by malignancy

          -  Non-malignant CNS disease such as stroke, epilepsy, CNS vasculitis, or
             neurodegenerative disease

          -  Clinically significant cardiovascular disease

          -  Positive serologic test results for HIV infection

          -  Positive serologic or polymerase chain reaction (PCR) test results for Hepatitis B
             (HBV) infection

          -  Positive serologic and PCR test results for Hepatitis C (HCV) infection

          -  Live vaccine <6 weeks prior to start of lympho-conditioning

          -  Known allergy to albumin (human) or DMSO